Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.

Frange P, Blanche S, Chaix ML.

J Antimicrob Chemother. 2013 Nov;68(11):2694-5. doi: 10.1093/jac/dkt215. Epub 2013 Jun 5. No abstract available.

PMID:
23743089
2.

Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.

Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f.

PMID:
20739898
3.

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

Frange P, Briand N, Avettand-fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML.

Pediatr Infect Dis J. 2011 Aug;30(8):684-8. doi: 10.1097/INF.0b013e31821752d6.

PMID:
21427626
4.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
5.

Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.

Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M, Speck R, Weber R; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):51-8. doi: 10.1097/QAI.0b013e3181bef889.

PMID:
19838125
6.

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.

Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M; ARCA Collaborative Group.

AIDS. 2010 Apr 24;24(7):1013-8. doi: 10.1097/QAD.0b013e328336e962.

PMID:
20124969
7.

Preserving future therapeutic options: should we limit the lamivudine use in young HIV-1 infected children initiating first-line HAART?

Frange P, Chaix ML, Blanche S.

AIDS. 2013 Jan 14;27(2):151-4. doi: 10.1097/QAD.0b013e32835a99f1. No abstract available.

PMID:
23032408
8.
9.

Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.

Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.

Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):399-402. doi: 10.1007/s10096-008-0636-x. Epub 2008 Oct 8.

PMID:
18841401
10.

Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.

Ferrer E, Niubo J, Crespo M, Gatell JM, Sanz J, Veloso S, Llibre JM, Barrufet P, Sanchez P, Podzamczer D; ABCDE Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):253-5. No abstract available.

PMID:
17895768
11.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.

J Antimicrob Chemother. 2012 Jun;67(6):1475-8. doi: 10.1093/jac/dks047. Epub 2012 Feb 26.

PMID:
22371439
12.

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.

Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.

Pediatr Infect Dis J. 2006 Nov;25(11):1049-56.

PMID:
17072129
13.

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.

Cahn P, Wainberg MA.

J Antimicrob Chemother. 2010 Feb;65(2):213-7. doi: 10.1093/jac/dkp422. Epub 2009 Dec 9. Review.

PMID:
20007333
14.

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.

Ross LL, Parkin N, Gerondelis P, Chappey C, Underwood MR, St Clair MH, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):567-70.

PMID:
17075395
15.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
16.

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.

Pollock K, Stebbing J, Bower M, Gazzard B, Nelson M.

J Antimicrob Chemother. 2006 Jul;58(1):227-8. Epub 2006 May 9. No abstract available.

PMID:
16684800
17.

Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.

Ford N, Shubber Z, Hill A, Vitoria M, Doherty M, Mills EJ, Gray A.

PLoS One. 2013 Nov 11;8(11):e79981. doi: 10.1371/journal.pone.0079981. eCollection 2013. Review.

18.

Assessment of the relative potency of emtricitabine and lamivudine.

Schinazi RF.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):243-5; author reply 245-6. No abstract available.

PMID:
14526216
19.

A controlled trial of initial antiviral regimens for HIV-1 infection.

Parienti JJ.

N Engl J Med. 2010 Mar 4;362(9):854; author reply 855. doi: 10.1056/NEJMc0912879. No abstract available.

20.

Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.

Re MC, Monari P, Bon I, Borderi M, Gibellini D, Schiavone P, Vitone F, Furlini G, La Placa M.

Int J Antimicrob Agents. 2002 Sep;20(3):223-6.

PMID:
12385703

Supplemental Content

Support Center